Tum- mutation P35B generates the MHC-binding site of a new antigenic peptide.
Immunogenic tumor cell variant P35 was obtained by mutagen treatment of mouse mastocytoma P815. It expresses a potent new antigen recognized by syngeneic cytolytic T lymphocytes (CTL). This antigen is the result of a point mutation in a gene that is expressed by most healthy cells. A decapeptide encoded by the region spanning the mutation sensitized P815 cells to the relevant CTL, whereas the homologous decapeptide corresponding to the normal sequence did not. Only the mutant decapeptide was capable of enhancing the expression of the Dd-presenting molecule at the cell surface, indicating that the mutation generates a motif which enables the antigenic peptide to bind to Dd.
Szikora
J P
JP
Ludwig Institute for Cancer Research, Brussels, Belgium.
Van Pel
A
A
Boon
T
T
D000595:Amino Acid Sequence; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D001483:Base Sequence; D001665:Binding Sites; D004273:DNA, Neoplasm; D005434:Flow Cytometry; D006649:Histocompatibility Antigens / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D012515:Mast-Cell Sarcoma; D051379:Mice; D008811:Mice, Inbred DBA; D008969:Molecular Sequence Data; D017354:Point Mutation; D017386:Sequence Homology, Amino Acid; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D004273:DNA, Neoplasm; D006649:Histocompatibility Antigens; C029237:tumor-associated transplantation antigen